Precision BioSciences, Inc. is a clinical-stage gene editing company focused on developing in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company offers ARCUS, a genome editing platform designed to address genetic disorders. Precision BioSciences also provides ex vivo allogeneic CAR T Immunotherapy, which involves genetically engineering T cells to specifically target and eliminate cancer cells. The company’s lead candidate, PBCAR0191, is currently undergoing a Phase 1/2a clinical trial aimed at treating adult patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL) or B-cell precursor acute lymphoblastic leukemia (B-ALL). Another significant candidate is PBCAR19B, which is designed to minimize the risk of chromosomal abnormalities by utilizing a single-step gene edit on the stealth cell platform. Additionally, the investigational PBCAR269A targets BCMA for the treatment of relapsed/refractory multiple myeloma. The company has established development and commercial license agreements with Les Laboratoires Servier to create allogeneic chimeric antigen receptor T cell therapies addressing various hematological cancer targets and solid tumors. Furthermore, collaborations with Tiziana Life Sciences and iECURE, Inc. aim to explore the potential of foralumab as a lymphodepleting agent and to develop ARCUS-based gene editing therapies, respectively. The EBITDA ratio is 0.20 highlighting the company's operational efficiency, while it achieved a revenue of $68,696,000.00 indicating its niche market focus. The reported income before tax stands at $7,167,000.00 showcasing its pre-tax profitability. Additionally, the gross profit is $64,119,000.00 reflecting the company's profitability from core operations. The operating income ratio is -0.38 indicating a solid margin in terms of operational profitability. The stock is affordable at $4.92 making it suitable for budget-conscious investors. Despite its value, the stock has a low average trading volume of 139,085.00 indicating lower market activity relative to larger companies. With a market capitalization of $53,556,165.00 Precision BioSciences is classified as a small-cap player. It plays a crucial role in the Biotechnology industry, contributing significantly to the overall market landscape, particularly in the field of gene editing and immunotherapy. Moreover, it belongs to the Healthcare sector, driving innovation and growth as it advances potential therapies that could transform treatment options for patients facing serious health challenges.